SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BRAVEHEART who wrote (455)2/1/1999 9:30:00 PM
From: scaram(o)uche  Read Replies (1) of 4474
 
Before the Penn/ARIAD group pursues clinical trials with its system, ARIAD scientists will take a rapamycin analog into a
simple Phase I trial to prove that it is nontoxic. Penn researchers will take the vector alone, minus rapamycin, into the clinic to
establish its safety. The Penn group plans, by no later than January 1, 2001, to unite the vector with the regulated system in a
clinical trial targeting thalassemia, a severe inherited anemia.

Sure would have been great to have some osteoporosis, unrelated-sidebar-stuff somewhere in the article. Or some "unique capacities developed at the Genomics Center"-stuff.

When we started this thread, we used to discuss signal intervention, and ARGENT was this great project on the side.

Great link. Thanks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News